NFKBIA and breast cancer: In addition, FBXO32 targets IκBα proteasome degradation in breast and human kidney transformed cells, while FBXO32 contributes the activation of NF-κB pathway in various tissues, while also exacerbating inflammation and genotoxic stress in breast cancer MCF7 cells (27).